about
Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients.Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma?Mutational profile of primary breast diffuse large B-cell lymphoma.Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer.Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients.Long-term follow up of Hodgkin lymphoma.Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signalingSentinel lymph node biopsy in breast cancer: the role of micrometastasisClinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotypingTreatment of induction in resectable NSCLC with chemotherapy, followed by surgery and erlotinibNeoadjuvant treatment with tyrosine kinase inhibitors in patients with resectable non-small cell lung cancerConsolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-yearsNivolumab-associated digital small-vessel vasculitis in a patient with an advanced renal cell carcinomaCisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition
P50
Q41708757-7D4C276F-BFD7-4B37-92A4-6EDD234A58E9Q41740108-77591A0E-4BEA-486A-8C3F-82812D1941BDQ47118882-78682940-9387-46CE-AD1A-4799E5FB605BQ47153324-7D11234C-7CA5-413E-9ED2-39E0FDCE8E5EQ48499401-34B7112A-C151-4FA0-847D-6765D348D378Q55002602-9A6D4306-5B4F-45FA-BE63-FAE6DAAF2739Q58553337-BBDC48F1-5DAD-483A-A89A-2FBB2582E8E7Q86563384-076F0FBD-89F6-4621-93DF-A8CA64DAE4E2Q90392076-2AA1247E-33AA-4B46-950B-3E84F7BE5AC0Q90911544-763973E4-4A95-409C-990E-28D1A621826AQ91318172-FC052BA9-22C1-4E6B-A587-3486D9110CB6Q91572054-3A8BF137-28D6-4784-92DC-CA235A3EE4F8Q91755207-7EEC69CA-4E6B-4A0C-AAD4-AE5EF005F35CQ92422009-B638FB34-15F8-4B0F-9B7D-CB930B559E70
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Fernando Franco
@en
Fernando Franco
@nl
type
label
Fernando Franco
@en
Fernando Franco
@nl
prefLabel
Fernando Franco
@en
Fernando Franco
@nl
P31
P496
0000-0001-8964-5136